ABSTRACT
In managing HIV/AIDS with highly active antiretroviral agents, the historical therapeutic aim remains to maintain the plasma concentrations at a level above the half maximal inhibitory concentration (IC50) required for 50% inhibition in viral replication. Concentration dependent toxicity is often observed in patients with elevated drug exposure and high peak plasma levels in lieu accurately calculated drug dosages. Similarly low plasma concentrations are frequently witnessed in individuals receiving adequate dosage regimens. Pharmacogenetic variations in drug metabolizing enzymes may contribute to this phenomenon. Over the last decade, knowledge about the role of pharmacogenetics in the treatment and prediction of ARV plasma levels have increased significantly. However, the extent of these genetic variations remain largely unknown in the South African population,which has sparked a renewed enthusiasm for local pharmacogenetic studies
ABSTRACT
In managing HIV/AIDS with highly active antiretroviral agents, the historical therapeutic aim remains to maintain the plasma concentrations at a level above the half maximal inhibitory concentration (IC50) required for 50% inhibition in viral replication.Concentration dependent toxicity is often observed in patients with elevated drug exposure and high peak plasma levels in lieu of accurately calculated drug dosages. Similarly lowplasmaconcentrationsarefrequently witnessed in individuals receiving adequate dosage regimens. Pharmacogenetic variations in drug metabolizing enzymes may contribute to this phenomenon.Over the last decade, knowledge about the role of pharmacogenetics in the treatment and prediction of ARV plasma levels have increased significantly. However, the extent of these genetic variations remain largely unknown in the South African population,which has sparked a renewed enthusiasm forlocalpharmacogenetic studies
Subject(s)
Delavirdine , Nucleosides , Polymorphism, Genetic , Protease Inhibitors , Reverse Transcriptase InhibitorsABSTRACT
As part of an effort to develop new lumaphors involving late transition metal ions, this report describes the synthesis and characterization of the first platinum(II) derivatives containing 2,2':6',2''-terpyridine (trpy) and cyanide as co-ligands. According to existing models, including cyanide in the coordination sphere should raise the energies and minimize the influence of short-lived d-d excited states that otherwise compromise the excited-state lifetime. Both [Pt(trpy)(CN)]+ and the 4'-cyano-2,2':6',2''-terpyridine analogue [Pt(CN-T)(CN)]+ are emissive in dichloromethane solution, but the signals are weak. Part of the problem is that the d-pi* charge-transfer excited states also rise in energy, so that the emission actually originates from a (3)pi-pi* state with a relatively low radiative rate constant. However, another member of the series, the 4'-dimethylamino-2,2':6',2''-terpyridine (dma-T) derivative [Pt(dma-T)(CN)]+, proves to be a very promising platform with an emission quantum yield of phi= 0.26 and an excited-state lifetime of tau = 22 micros in room-temperature, deoxygenated dichloromethane solution. In the dma-T complex the electron-rich dimethylamino substituent provides the basis for an emissive, but largely ligand-based, charge-transfer excited state. The orbital parentage is such that the photoluminescence persists in donating solvents like dimethylformamide, which ordinarily quenches d-pi* excited states in complexes of this type.
